In July 2026, Akso Health Group reported full-year results for the period ended March 31, 2026, showing sales of US$13.84 million and a net loss of US$18.67 million, alongside materially lower loss per share than a year earlier. On the same date, auditor CHI-LLTC issued an unqualified opinion but raised substantial doubt about Akso Health Group’s ability to continue as a going concern, highlighting serious questions about its financial resilience despite narrowed losses. We’ll now examine...
/PRNewswire/ -- Akso Health Group (NASDAQ: AHG) ("Akso Health" or the "Company") today announced the commencement of its next-generation, proprietary...
--Akso Health Group today announced the launch of the an exploratory patient support program and a strategic cooperation with Nanning Duoling Research Institute. Akso Health plans to open its global medical network, connecting the radiation oncology centers under its planning and construction withtargeted drugs andremote consultation teams.